中国癌症负担概述及对策。
Overview and countermeasures of cancer burden in China.
机构信息
NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China.
Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China.
出版信息
Sci China Life Sci. 2023 Nov;66(11):2515-2526. doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.
Abstract
Cancer is one of the leading causes of human death worldwide. Treatment of cancer exhausts significant medical resources, and the morbidity and mortality caused by cancer is a huge social burden. Cancer has therefore become a serious economic and social problem shared globally. As an increasingly prevalent disease in China, cancer is a huge challenge for the country's healthcare system. Based on recent data published in the Journal of the National Cancer Center on cancer incidence and mortality in China in 2016, we analyzed the current trends in cancer incidence and changes in cancer mortality and survival rate in China. And also, we examined several key risk factors for cancer pathogenesis and discussed potential countermeasures for cancer prevention and treatment in China.
摘要
癌症是全球范围内导致人类死亡的主要原因之一。癌症的治疗耗费了大量的医疗资源，其发病率和死亡率给社会带来了巨大的负担。因此，癌症已成为全球共同面临的严重经济和社会问题。在中国，癌症的发病率不断上升，这给中国的医疗体系带来了巨大的挑战。根据《国家癌症中心杂志》最近公布的 2016 年中国癌症发病率和死亡率数据，我们分析了中国癌症发病率的现状和变化趋势，以及癌症死亡率和生存率的变化，并探讨了癌症发病的一些关键风险因素，讨论了中国癌症防治的潜在对策。
相似文献
1
Overview and countermeasures of cancer burden in China.中国癌症负担概述及对策。
Sci China Life Sci. 2023 Nov;66(11):2515-2526. doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.
2
Analysis of status and countermeasures of cancer incidence and mortality in China.中国癌症发病与死亡分析及对策
Sci China Life Sci. 2019 May;62(5):640-647. doi: 10.1007/s11427-018-9461-5. Epub 2019 Mar 12.
3
[Comparison of the latest cancer statistics, cancer epidemic trends and determinants between China and the United States].[中美最新癌症统计数据、癌症流行趋势及决定因素的比较]
Zhonghua Zhong Liu Za Zhi. 2024 Jul 23;46(7):646-656. doi: 10.3760/cma.j.cn112152-20240208-00068.
4
Cancer registration in China and its role in cancer prevention and control.中国的癌症登记及其在癌症防控中的作用。
Lancet Oncol. 2020 Jul;21(7):e342-e349. doi: 10.1016/S1470-2045(20)30073-5.
5
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
6
Italian cancer figures, report 2012: Cancer in children and adolescents.《2012年意大利癌症数据报告：儿童和青少年癌症》
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.
7
National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data.中国 2005-20 年的癌症负担的国家和省级趋势：基于国家死亡率监测数据的分析。
Lancet Public Health. 2023 Dec;8(12):e943-e955. doi: 10.1016/S2468-2667(23)00211-6.
8
[Disease burden of liver cancer in China: an updated and integrated analysis on multi-data source evidence].《中国肝癌的疾病负担：基于多数据源证据的更新与综合分析》
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Nov 10;41(11):1848-1858. doi: 10.3760/cma.j.cn112338-20200306-00271.
9
China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations.中国卒中报告 2019：国家医疗质量管理与控制中心神经系统疾病专家委员会，国家神经系统疾病临床医学研究中心，中国卒中学会，国家心血管病中心，中国疾病预防控制中心，全球神经科学与卒中协作组织联合报告。
Stroke Vasc Neurol. 2020 Sep;5(3):211-239. doi: 10.1136/svn-2020-000457. Epub 2020 Aug 21.
10
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.中国癌症发病率、死亡率和疾病负担的变化趋势分析：基于 2020 年全球公布的流行病学数据与美国和英国的比较
Cancer Commun (Lond). 2021 Oct;41(10):1037-1048. doi: 10.1002/cac2.12197. Epub 2021 Jul 20.
引用本文的文献
1
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.靶向磷脂酰肌醇蛋白聚糖-3用于肝癌治疗：临床应用与检测方法
J Clin Transl Hepatol. 2025 Aug 28;13(8):665-681. doi: 10.14218/JCTH.2025.00099. Epub 2025 Aug 7.
2
Integrin factor (FAM27E3), as a metastatic marker of papillary thyroid carcinoma, through the p53 signaling pathway promoting lymph node metastasis.整合素因子（FAM27E3）作为甲状腺乳头状癌的转移标志物，通过p53信号通路促进淋巴结转移。
Front Genet. 2025 Jul 30;16:1593553. doi: 10.3389/fgene.2025.1593553. eCollection 2025.
3
Predicting hypoglycemia risk after gastrointestinal surgery in type 2 diabetes mellitus: a retrospective cohort study.预测2型糖尿病患者胃肠手术后的低血糖风险：一项回顾性队列研究。
Front Endocrinol (Lausanne). 2025 Jul 7;16:1590780. doi: 10.3389/fendo.2025.1590780. eCollection 2025.
4
Risk factors of bone metastasis in lung adenocarcinoma.肺腺癌骨转移的危险因素
BMC Pulm Med. 2025 Jul 2;25(1):299. doi: 10.1186/s12890-025-03702-0.
5
Impact of tertiary lymphoid structure-associated biomarkers on pancreatic cancer via a dual-disease analysis of psoriasis and pancreatic cancer.通过银屑病和胰腺癌的双重疾病分析探讨三级淋巴结构相关生物标志物对胰腺癌的影响
Discov Oncol. 2025 Jul 1;16(1):1247. doi: 10.1007/s12672-025-03082-1.
6
Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) Before Treatment as the Predictive Indicators for Bone Metastasis in Prostate Cancer Patients.老年营养风险指数（GNRI）和治疗前预后营养指数（PNI）作为前列腺癌患者骨转移的预测指标
Int J Gen Med. 2025 May 24;18:2703-2713. doi: 10.2147/IJGM.S516768. eCollection 2025.
7
The experience and needs of self-care in elderly colorectal cancer stoma patients: a qualitative study.老年结直肠癌造口患者自我护理的经验与需求：一项定性研究
Support Care Cancer. 2025 May 15;33(6):474. doi: 10.1007/s00520-025-09530-6.
8
Clofoctol impairs the stemness of gastric cancer and induces TNF-mediated necroptosis by directly binding to RanBP2.氯伏克托通过直接结合RanBP2来损害胃癌的干性并诱导肿瘤坏死因子介导的坏死性凋亡。
Cell Mol Life Sci. 2025 May 6;82(1):194. doi: 10.1007/s00018-025-05723-8.
9
Exploring the Potential Link Between Autoimmune Diseases and Pan-Cancer: A Multidatabase Mendelian Randomization Analysis.探索自身免疫性疾病与泛癌之间的潜在联系：一项多数据库孟德尔随机化分析
J Immunol Res. 2025 Apr 27;2025:6468979. doi: 10.1155/jimr/6468979. eCollection 2025.
10
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.抗体药物偶联物（ADCs）：当前及未来的生物制药
J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3.
本文引用的文献
1
Cancer incidence and mortality in China, 2016.2016年中国癌症的发病率和死亡率
J Natl Cancer Cent. 2022 Feb 27;2(1):1-9. doi: 10.1016/j.jncc.2022.02.002. eCollection 2022 Mar.
2
A Study on the Prediction of Cancer Using Whole-Genome Data and Deep Learning.一项关于利用全基因组数据和深度学习预测癌症的研究。
Int J Mol Sci. 2022 Sep 8;23(18):10396. doi: 10.3390/ijms231810396.
3
The epidemic of thyroid cancer in China: Current trends and future prediction.中国甲状腺癌的流行情况：当前趋势与未来预测。
Front Oncol. 2022 Sep 2;12:932729. doi: 10.3389/fonc.2022.932729. eCollection 2022.
4
The cross-talk of cancer-associated fibroblasts assist in prognosis and immunotherapy in patients with breast carcinoma.癌症相关成纤维细胞的相互作用有助于乳腺癌患者的预后评估和免疫治疗。
Cancer Gene Ther. 2022 Dec;29(12):2001-2012. doi: 10.1038/s41417-022-00514-w. Epub 2022 Aug 10.
5
Epithelial-Mesenchymal Transition-Mediated Tumor Therapeutic Resistance.上皮-间质转化介导的肿瘤治疗抵抗
Molecules. 2022 Jul 25;27(15):4750. doi: 10.3390/molecules27154750.
6
Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.利用 EPR 效应和其他靶向机制增强药物递送至实体瘤的策略。
Adv Drug Deliv Rev. 2022 Sep;188:114449. doi: 10.1016/j.addr.2022.114449. Epub 2022 Jul 11.
7
Protecting People from Tobacco Smoke in China: Current Status and Challenges.中国保护人们免受烟草烟雾危害：现状与挑战。
China CDC Wkly. 2022 May 27;4(21):460-464. doi: 10.46234/ccdcw2022.102.
8
Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.肝胆肿瘤类器官揭示 HLA I 类新抗原景观和免疫检查点抑制剂增强的新抗原肽的抗肿瘤活性。
Adv Sci (Weinh). 2022 Aug;9(22):e2105810. doi: 10.1002/advs.202105810. Epub 2022 Jun 5.
9
Air pollution: A culprit of lung cancer.空气污染：肺癌的一个元凶。
J Hazard Mater. 2022 Jul 15;434:128937. doi: 10.1016/j.jhazmat.2022.128937. Epub 2022 Apr 15.
10
Advances in tests for colorectal cancer screening and diagnosis.结直肠癌筛查与诊断检测的进展。
Expert Rev Mol Diagn. 2022 Apr;22(4):449-460. doi: 10.1080/14737159.2022.2065197. Epub 2022 Apr 15.
Zotero 插件